Shares of Novo Nordisk retreated by as much as 7% on Monday, even as the pharmaceutical giant presented a $23 billion sales target for its leading obesity treatments. The decline came despite optimistic revenue projections, as investors digested warnings about upcoming patent expirations.
During the company’s Capital Markets Day in London, CEO Mike Doustdar addressed what he termed the “elephant in the room”: the impending loss of key patent protections for semaglutide. The molecule serves as the active ingredient in Wegovy and Ozempic, the company’s flagship weight-loss and diabetes medications. In the United States, which generates over half of the drug’s sales, exclusivity is scheduled to expire in 2032.
“Semaglutide is what’s on most people’s mind, and rightfully so,” Doustdar acknowledged. He noted that the company’s success had attracted intense competition, stating, “We created an incredibly attractive market, and now almost every other single pharma company, big or small, is trying to come and compete with us. We need to be ready for that.”
Doustdar outlined strategies to diversify the firm’s portfolio in anticipation of the transition. He emphasized that Novo Nordisk does not underestimate the pressures associated with loss of exclusivity (LOE), particularly regarding potential price erosion. However, he expressed confidence in the company’s long-term trajectory.
“We plan to come on the other side of the LOE as a bigger company than we are today and a much more diversified version of it,” Doustdar said.
Semaglutide built this empire, but relying on one molecule was always risky. Smart move to pivot early, even if markets hate it.
Is 2032 really too late to worry? With so many competitors entering now, won’t prices start dropping well before then?
Wow, a twenty-three billion sales target and the stock still tanks? The market fears generic competition more than current profits.
Seven percent drop is brutal. Investors clearly aren’t buying the diversification story enough to ignore patent cliffs.